永和智控(002795.SZ):可行權的股票期權數量為737.8萬份
格隆匯2月21日丨永和智控(002795.SZ)發佈關於公司2019年股票期權激勵計劃第二個行權期採用自主行權模式的提示性公吿,公司2019年股票期權激勵計劃簡稱:永和JLC1,股票期權代碼:037852;公司第二個行權期可行權的激勵對象為19名,可行權的股票期權數量737.80萬份,佔公司目前總股本的3.53%,行權價格為14.19元/股;
此次行權採用自主行權模式;公司第二個行權期可行權期限為2022年2月24日至2023年2月23日,根據行權手續辦理情況,實際可行權期限為2022年2月24日至2023年2月23日;
此次可行權股票期權若全部行權,公司股份仍具備上市條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.